Stock Details
4523.T is Eisai Co., Ltd.'s stock. Stock exchange Tokyo (Currency JPY). Average price in 50 days is 8,076.96¥. Average daily volumn in 3 months 2.3M. Market cap 2.74T



Stock symbol : 4523.T. Exchange : Tokyo. Currency : JPY
Lastest price : 9,555.00¥. Total volume : 4.43M. Market state POSTPOST
Click reload if you want to check the lastest price on market!!!

Eisai Co., Ltd. (4523.T)
Last Price
9,555.00¥
Change
-220.00
Volume
4.43M

Previous Close9,775.00
Open9,634.00
Day Range9,482.00-9,674.00
Bid9,546.00 x N/A
Ask9,557.00 x N/A
Volume4.43M
Average Volume2.3M
Market Cap2.74T
Beta0.20
52 Week Range5,011.00-9,674.00
Trailing P/E84.62
Foward P/E51.02
Dividend (Yield %)1.78%
Ex-Dividend Date2023-03-30



Financial Details


According to Eisai Co., Ltd.'s financial reports the company's revenue in 2022 were 756.23B an increase( +17.21%) over the years 2021 revenue that were of 645.94B. In 2022 the company's total earnings were 47.95B while total earnings in 2021 were 42.12B( +11.9%).


Loading ...



Organization

eisai-co-ltd-logo

Eisai Co., Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer's disease/dementia with Lewy bodies; Methycobal for the treatment of peripheral neuropathy; and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures. The company also provides Lyrica for pain treatment; Dayvigo, an anti-insomnia drug for the treatment of adults with insomnia; Lenvima, an anticancer agent/molecular targeted... medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; and Halaven, an anticancer agent/microtubule dynamics inhibitor for the treatment of breast cancer and liposarcoma. In addition, it offers Pariet, a proton-pump inhibitor for the treatment of gastric and duodenal ulcers, reflux esophagitis, and eradication of Helicobacter pylori infections, etc.; Humira, a fully human anti-TNF-a monoclonal antibody for the treatment of autoimmune diseases, such as rheumatoid arthritis; and Chocola BB plus, a vitamin B2 preparation for rough skin and stomatitis, as well as various products, which include third-class OTC drugs, designated quasi-drugs, and food with nutrient function. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.

Market Cap:
2.74T
Revenue:
756.23B
Total Assets:
1.24T
Total Cash:
309.63B



News about "Eisai Co., Ltd."

eisai-biogen-alzheimers-drug-could-be-available-to-some-next-year-image

Eisai, Biogen Alzheimer's drug could be available to some next year

Source from : Reuters on MSN - 1 days ago

The logo of Eisai Co Ltd is displayed at the company headquarters in Tokyo, Japan, March 8, 2018. REUTERS/Issei Kato/File Photo ...See details»


Japanese drugmaker Eisai's shares drop on report of death in Alzheimer's trial

Source from : Reuters - 2 days ago

The logo of Eisai Co Ltd is displayed at the company headquarters in Tokyo, Japan, March 8, 2018. REUTERS/Issei Kato ...See details»


eisai-alzheimers-drug-sparks-hot-debate-over-benefits-as-risks-like-brain-bleeding-emerge-image

Eisai Alzheimer’s Drug Sparks Hot Debate Over Benefits as Risks Like Brain Bleeding Emerge

Source from : Bloomberg on MSN - 2 days ago

Eisai Co.’s much-anticipated findings on its experimental Alzheimer’s drug provided tinder for a debate over whether its modest efficacy is worth potential risks that include serious brain bleeding.See details»


eisai-announces-approval-of-partial-change-to-label-for-dosage-and-administration-of-aricept-for-treatment-of-dementia-with-lewy-bodies-image

Eisai Announces Approval of Partial Change to Label for Dosage and Administration of Aricept for Treatment of Dementia with Lewy Bodies

Source from : Asia One - 3 days ago

Eisai Co., Ltd. announced that its application for a partial change to label for Aricept (donepezil hydrochloride), a treatment for Alzheimer's disease and dementia with Lewy bodies (DLB) that ...See details»


Eisai Co. Ltd. ADR

Source from : Wall Street Journal - 21 days ago

Yoshiteru Kato Director Eisai Co., Ltd., Eisai Manufacturing Ltd. Hiroyuki Kato Director Eisai Co., Ltd. Hideki Hayashi Director Eisai Co., Ltd., Ea Pharma Co., Ltd ...See details»


Eisai Co., Ltd. (4523.T)

Source from : Yahoo Finance - 6 days ago

*Close price adjusted for splits.**Adjusted close price adjusted for splits and dividend and/or capital gain distributions. Loading more data ...See details»


Eisai to Present Preclinical and Clinical Research on Eribulin at the 2022 San Antonio Breast Cancer Symposium

Source from : JCN Newswire - 1 days ago

Eisai Co., Ltd. announced today that new study results on its in-house discovered and developed anticancer agent eribulin mesylate (HALAVEN, "eribulin") will be presented during (SABCS), which is ...See details»


alzheimers-drug-not-to-blame-for-hemorrhage-deaths-eisai-says-image

Alzheimer’s Drug Not to Blame for Hemorrhage Deaths, Eisai Says

Source from : Bloomberg L.P. on MSN - 2 days ago

Eisai Co. said lecanemab, the drug it’s developing with Biogen Inc., isn’t to blame for two deaths involving brain bleeding that occurred in an Alzheimer’s disease treatment trial.See details»


Eisai Shares Fall Following Report of Patient Death in Alzheimer's Trial

Source from : Morningstar%2c Inc. - 3 days ago

Eisai Co.'s shares fell Tuesday following a report that a woman died after receiving the company's experimental Alzheimer's drug. Eisai's shares fell as much as 12% to Y8,473 and were recently 9.9 ...See details»


‘We were right all along:’ For Japanese drugmaker Eisai, success against Alzheimer’s has been a long time coming

Source from : STAT - 15 days ago

In 1997, Eisai launched Aricept, a revolutionary treatment for the symptoms of Alzheimer’s disease, invented and developed by the company’s scientists in Japan. The arrival of the drug was a ...See details»


Eisai Satisfies All-case Study Requirement for Antiepileptic Agent Inovelon

Source from : Benzinga.com - 28 days ago

TOKYO, Nov 2, 2022 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has received notification from Japan's Ministry of Health, Labour, and Welfare (MHLW) that the "all-case study ...See details»


Eisai, Biogen say Alzheimer’s drug succeeds in slowing cognitive decline

Source from : 朝日新聞社 - 22 days ago

Eisai Co. Ltd. and Biogen Inc. on Tuesday said their experimental Alzheimer’s drug significantly slowed cognitive and functional decline in a large trial of patients in the early stages of the ...See details»


Eisai to Present Latest Data on Perampanel at the 76th American Epilepsy Society (AES) Annual Meeting

Source from : Benzinga.com - 8 days ago

TOKYO, Nov 24, 2022 - (JCN Newswire) - Eisai Co., Ltd. announced today that the company will have a total of 34 poster presentations, including the latest data on its in-house discovered and ...See details»


BioArctic's partner Eisai presents results of lecanemab Phase 3 confirmatory Clarity AD study for Early Alzheimer's disease at CTAD conference

Source from : Yahoo Finanzas - 2 days ago

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the results from the large global Phase 3 confirmatory Clarity AD clinical study of lecanemab (development code: ...See details»